

26 January 2023

Diaceutics PLC
("Diaceutics" or "the Company")

US\$ 7 million multi-year enterprise engagements for subscription data services

Validating the Group's strategy and platform technology investments to date

[Diaceutics PLC](#) (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical industry, is pleased to announce two enterprise-level, multi-disease data engagements, with two top 10 global pharmaceutical companies. Combined, the contracts will deliver a cumulative value of US\$ 7 million over a two year period, demonstrating Diaceutics' continued successful transition to a subscription based model and further validating the Group's strategy and platform technology investments to date.

Diaceutics will deliver a number of subscription data services to help these global pharmaceutical organisations commercialise their therapeutic treatments more quickly, accurately and efficiently, increasing the uptake by eligible patients and enhancing the organisations' return on R&D investment.

The subscription data services, delivered via Diaceutics' proprietary DXRX platform, include the following products:

- **Signal**, which uses real-world data through DXRX's network of labs to identify patients who have tested positively for a particular biomarker and are therefore suitable for certain precision medicines;
- **Lab Mapping**, which provides an in-depth analysis of the lab environment to determine key factors in commercialising the precision medicine;
- **Physician Mapping**, which examines physician testing behaviour to determine testing rates - a leading indicator for prescription - and the critical physician-to-lab relationship; and
- **Disease Testing Rate Tracker**, which delivers an accurate view of testing rates, adoption and trends over time.

Diaceutics has also developed an innovative suite of commercialisation solutions and advisory services, which can be delivered through its proprietary DXRX platform, and offer additional opportunities to expand the scale and coverage of these customer engagements.

Peter Keeling, Chief Executive Officer of Diaceutics, said:

"These enterprise level engagements are a testament to the value placed in our expanding offerings by pharmaceutical and life science organisations.

The continued strong pipeline build serves to highlight the scale of the opportunity available to us within the market, as we continue to further embed within existing customers and onboard new top pharma companies to the DXRX platform.

Looking ahead, our position as a trusted precision medicine partner grants us a unique opportunity to expand our offerings beyond initial data insights and into our full suite of commercialisation solutions and advisory services."

Enquiries:

Diaceutics PLC

Peter Keeling, Chief Executive Officer
Nick Roberts, Chief Financial Officer

Via Alma PR

Stifel Nicolaus Europe Limited (Nomad & Broker)

Ben Maddison
Stewart Wallace
Nick Adams

Tel: +44 (0)20 7710 7600

Alma PR

Caroline Forde
Kieran Breheny
Matthew Young

Tel: +44(0)20 3405 0205
diaceutics@almapr.co.uk

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharmaceutical and life science companies with solutions and technology for the commercialisation of their precision medicines, enabled by the proprietary DXRX platform.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real-world healthcare data insights, advisory services and innovative platform enabled solutions.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCUVOARORUAUUR